 Glycosylated hemoglobin A1c HbA1c, a reliable test to assess chronic glycemia and recommended both for the diagnosis and monitoring of T2DM, is neither accurate nor reliable in patients with cirrhosis. A validation study has not been performed to define its true usefulness in the setting of cirrhosis. The study aims to determine the level of HbA1c that better corresponds to the diagnosis of T2DM - as determined by an oral glucose tolerance test OGTT - and to correlate the levels of HbA1c with the average glucose over a 12-week period in patients with cirrhosis and known T2DM, in cirrhotic patients with different degrees of liver impairment. This study is designed as a pilot, observational, cross-sectional Group A - cirrhotics with no T2DM and longitudinal study Group B - cirrhotics with known diabetes. For our first aim Group A the diagnostic yield of HbA1c for T2DM will be compared to that of an OGTT. Regarding the second aim Group B HbA1c will be compared to glucose reading from a continuous glucose monitor. In both groups, the following study labs will be performed: fructosamine, Complete Blood Count CBC, liver function tests, chemistry, International Normalized Ratio INR, and pre albumin. A total of 26 patients per group will be included. 